ChiCTR2300072224 版本V1.1 版本创建时间2023/07/26 21:49:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300072224 

最近更新日期:

Date of Last Refreshed on:

2023-06-07 11:26:16 

注册时间:

Date of Registration:

2023-06-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

甲字提毒药捻治疗难愈性窦道的临床评价研究

Public title:

Clinical evaluation study of Jia Zi Ti Du drug twists in the treatment of refractory sinus tract

注册题目简写:

English Acronym:

研究课题的正式科学名称:

甲字提毒药捻治疗难愈性窦道的临床评价研究

Scientific title:

Clinical evaluation study of Jia Zi Ti Du drug twists in the treatment of refractory sinus tract

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张董晓 

研究负责人:

张董晓 

Applicant:

Zhang Dongxiao 

Study leader:

Zhang Dongxiao 

申请注册联系人电话:

Applicant telephone:

+86 138 1107 7684

研究负责人电话:

Study leader's
telephone:

+86 138 1107 7684

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

morningdong@163.com

研究负责人电子邮件:

Study leader's E-mail:

morningdong@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市东城区美术馆后街23号

研究负责人通讯地址:

北京市东城区美术馆后街23号

Applicant address:

No. 23 Back Street of the Art Museum,Dongcheng District, Beijing

Study leader's address:

No. 23 Back Street of the Art Museum,Dongcheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京中医医院

Applicant's institution:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京中医医院

Affiliation of the Leader:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023BL02-035-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京中医医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-23 00:00:00

伦理委员会联系人:

刘声

Contact Name of the ethic committee:

Liu Sheng

伦理委员会联系地址:

北京市东城区美术馆后街23号

Contact Address of the ethic committee:

No. 23 Back Street of the Art Museum,Dongcheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8790 6734

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京中医医院

Primary sponsor:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

研究实施负责(组长)单位地址:

北京市东城区美术馆后街23号

Primary sponsor's address:

No. 23 Back Street of the Art Museum,Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

北京

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

首都医科大学附属北京中医医院

具体地址:

北京市东城区美术馆后街23号

Institution
hospital:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

Address:

No. 23 Back Street of the Art Museum,Dongcheng District, Beijing

经费或物资来源:

国家中医药管理局

Source(s) of funding:

National Administration of Traditional Medicine

研究疾病:

难愈性窦道  

Target disease:

Refractory sinus tract

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

针对甲字提毒药捻治疗难愈性窦道进行有效性、安全性及卫生经济学评价,形成临床研究证据,探讨甲字提毒药捻治疗窦道类疾病的优势所在,建立可靠、符合临床实际的治疗难愈性窦道的中医特色方案,为其临床推广应用提供依据。  

Objectives of Study:

The efficacy, safety and health economics evaluation of Jia Zi Ti Du drug twist in the treatment of refractory sinus tract were carried out, clinical research evidence was formed, the advantages of Jia Zi Ti Du drug twist in the treatment of sinus tract diseases were discussed, and a reliable and clinical practice TCM characteristic program for the treatment of refractory sinus tract was established to provide a basis for its clinical promotion and application.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(l)符合窦道疾病诊断。 (2)前期应用手术治疗、外科换药、中医治疗等方法(包括但不限于窦道切开或切除配合清创后换药、负压封闭引流、外科常规换药、自体富血小板血浆治疗、异体富血小板血浆治疗、掺药、贴敷、冲洗灌注疗法、纱条引流、负压拔罐等)进行治疗,且周期≥4周仍未愈合者。 (3)年龄在18~70岁(包括18岁和70岁)之间女性。 (4)窦道深度≥1厘米且≤4厘米。 (5)知情同意,志愿受试,能够配合医护人员进行治疗和护理工作,签署知情同意书者。

Inclusion criteria

(1)Meet the diagnostic criteria for sinus. (2)Those who are treated with surgical treatment, surgical dressing change, traditional Chinese medicine treatment and other methods in the early stage, and the sinus is still not healed for ≥ 4 weeks. (3)Women aged between 18~70 (including 18 and 70 years old); (4)The depth of sinus is ≥ 1 cm and ≤4 cm; (5)Informed consent, who can cooperate with treatment and sign the informed consent form.

排除标准:

(1)合并有心脑血管、肝脏、肾脏、造血系统等严重全身疾病或精神病患者。 (2)妊娠期、哺乳期及准备怀孕的妇女。 (3)过敏体质,或对实验药物过敏者。 (4)正在参加其他临床研究者。 (5)截止参与本课题之前,曾在本次疾病治疗过程中使用过甲字提毒药捻者或与药捻配方相似的治疗方法及手段。

Exclusion criteria:

(1)Patients with serious primary diseases such as cardiovascular and cerebrovascular, liver, kidney, hematopoietic system, or psychosis; (2)Women who are pregnant,lactating or trying to become pregnant; (3)Those who are allergies, or allergic to experimental drugs. (4)Those who are participating in other clinical trials. (5)As of the time of participating in this project, who had used Jia Zi Ti Du twister or a treatment method similar to the drug twister formula in the treatment of this disease.

研究实施时间:

Study execute time:

From 2023-06-10 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-10 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

甲字提毒药捻组

样本量:

100

Group:

Jia Zi Ti Du drug twist group

Sample size:

干预措施:

甲字提毒药捻换药

干预措施代码:

Intervention:

Dressing with Jia Zi Ti Du drug twist

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

北京 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京中医医院 

单位级别:

三甲 

Institution
hospital:

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

窦道治疗疗效(探针探查)

指标类型:

主要指标

Outcome:

Efficacy of sinus tract therapy (probe exploration)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

窦道治疗疗效(超声探查)

指标类型:

主要指标

Outcome:

Efficacy of sinus tract therapy (ultrasound exploration)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

窦道痊愈时间

指标类型:

次要指标

Outcome:

The time it takes for the sinus tract to heal

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

分泌物质地、性状、引流量

指标类型:

次要指标

Outcome:

The texture, character, drainage of secretions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疮口大小

指标类型:

次要指标

Outcome:

The size of sore

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

乳房疼痛VAS评分

指标类型:

次要指标

Outcome:

A VAS score for breast pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

副作用指标

Outcome:

Complete blood count

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能检查

指标类型:

副作用指标

Outcome:

Liver Function Tests

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能检查

指标类型:

副作用指标

Outcome:

Renal Function Tests

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生命体征

指标类型:

副作用指标

Outcome:

Vital signs

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

诊疗费用

指标类型:

附加指标

Outcome:

Consultation costs

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

None

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

可以通过邮件形式与研究负责人取得联系,征得同意后可获取相关数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Anyone can contact the study leader by email and get permission to access the data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究数据管理由本课题组负责,以确保临床试验数据的真实性、完整性、私密性和可溯源性。由项目负责人或其他被授权的研究者将信息填写入CRF表中。研究者将采用标准操作规程,以保证临床试验的质量控制和质量保证系统的实施。临床试验中所有观察结果和发现都将加以核实,以保证数据的可靠性,确保临床试验中各项结论来源于原始数据。在数据处理的每一阶段均采用质量控制,以保证所有数据可靠,处理正确。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This research group is responsible for data management to ensure the authenticity, integrity, privacy and traceability of clinical trial data. Information is entered into the CRF form by the program manager or other authorized investigator. Investigators will use standard operating procedures to ensure quality control of clinical trials and the implementation of quality assurance systems. All observations and findings in clinical trials will be verified to ensure data reliability and that conclusions in clinical trials are derived from the original data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-06-07 11:21:35